您的位置: 首页 > 农业专利 > 详情页

Second, the double disinfectant of GLP-1 / gluca receptor was used to treat non acrylic fatty diseases.
专利权人:
HANMI PHARM. CO. LTD.
发明人:
HWANG, Sang Youn,KIM, Jin Young,KIM, Seung Su,CHOI, In Young,JUNG, Sung Youb,KWON, Se Chang
申请号:
CL2017000638
公开号:
CL2017000638A1
申请日:
2017.03.15
申请国别(地区):
CL
年份:
2017
代理人:
摘要:
<; p >; This Invention Bertalanffy refers to a Pharmaceutical composition & acute; S & eacute; utica for the Prevention or treatment of Bertalanffy disease H & amp; non-alcoholic fatty liver & acute; lico includes a Dual receptor agonist of the glp-1 / glucag & amp Action & acute; n; n prolongedAnd an M & eacute; All for the Prevention or treatment of Bertalanffy disease H & amp; non-alcoholic fatty liver & amp; manage the composition that includes lico Bertalanffy.The composition & acute; The present Invention N & amp; n <; em >; <; / em >; has no side effect of weight gain and reduces the side effect of weight gain, which is a side effect of the therapeutic agents & eacute; conventional disease cosmeceuticals for H & nbsp; liver fatty Alcohol & OR Lico, acute;<; em >; and <; / em >; reduces the amount of Administrations of a Dual receptor agonist of the glp-1 / glucag Bertalanffy acci Bertalanffy prolonged, thereby Improving & iacute; Patient Comfort. In addition, the & nbsp; Dual receptor agonist of the glp-1 / glucag Bertalanffy Action & amp; extended the present Invention Bertalanffy enhances Sustainability and stability in vivo <; em >; <; / em >;. <; / p >;<;p>;LA PRESENTE INVENCIÓ;N SE REFIERE A UNA COMPOSICIÓ;N FARMACÉ;UTICA PARA LA PREVENCIÓ;N O TRATAMIENTO DE LA ENFERMEDAD DEL HÍ;GADO GRASO NO ALCOHÓ;LICO QUE INCLUYE UN AGONISTA DUAL DEL RECEPTOR DE GLP - 1 /GLUCAGÓ;N DE ACCIÓ;N PROLONGADA, Y UN MÉ;TODO PARA LA PREVENCIÓ;N O TRATAMIENTO DE LA ENFERMEDAD DEL HÍ;GADO GRASO NO ALCOHÓ;LICO QUE INCLUYE ADMINISTRAR LA COMPOSICIÓ;N. LA COMPOSICIÓ;N DE LA PRESENTE INVENCIÓ;N <;em>;YA <;/em>;SEA NO TIENE EFECTO SECUNDARIO DE GANANCIA DE PESO O REDUCE EL EFECTO SECUNDARIO DE GANANCIA DE PESO, QUE ES UN EFECTO SECUNDARIO DE LOS AGENTES TERAPÉ;UTICOS CONVENCIONALES PARA LA ENFERMEDAD DEL HÍ;GADO GRASO NO ALCOHÓ
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充